About Us

Our Mission

Toward the realization of a society of health and longevity

We aim to realize a society of health and longevity through the development of innovative and breakthrough medicines for people around the world who are unable to fully benefit from or have access to current treatments.

I love this photo of my mums hand reachi

Background

Toward a super-aging society

In 2022, the global aging rate is projected to be 10% and 16% by 2050. The elderly population will be 1.5 billion.

In 2050, the aging rate in Japan is projected to reach 38%

In order for each and every one of us to live a healthy, fulfilling, and vibrant life, it is desirable not only to have a long life, but also to extend healthy longevity and realize a healthy society with longevity.

Reference:

https://www8.cao.go.jp/kourei/whitepaper/w-2020/html/zenbun/s1_1_1.html

Paradigm Shift in Research on Healthy Longevity and Aging

In the past decade, a paradigm shift in research on healthy longevity and aging has been taking place.

The mechanisms of aging are being elucidated, and methods to control aging are being developed.

Focus on cellular and

immune aging

It has become clear that Alzheimer's disease, diabetes, atherosclerosis, chronic nephropathy, and other diseases are caused by cellular aging.
We are engaged in drug discovery research based on the elucidation of the mechanisms of action caused by aging immune cells.

Genomic instability
Telomere reduciton
Epigenetic changes
Decreased proteostasis
Decreased nutrient sensing function

Mitochondrial dysfunction

Cellular senescence

Depletion of stem cells

Delayed intercellular communication

Reference:
The Hallmarks of Aging, Cell 2013 1531194-1217DOI: (10.1016/j.cell.2013.05.039) https://www.cell.com/

Company Profile

Company name

Cyn-K Bio, Inc.

Establishment

January 30, 2023

Head Office

32 Yoshida Tachibana-cho, Sakyo-ku, Kyoto

Representative Director

Ryuji Ueno

Business description

Research and development, manufacturing, sales, etc. of pharmaceutical products

Members

We are a group of like-minded people with the same goal of exploring unlimited possibilities. We all come from different fields and have different technical backgrounds, but our passion for Cyn-K Bio unites us all.

CEO and Founder

Medical Inventor

Ryuji Ueno,

Graduated from Keio University School of Medicine
Doctor of Medicine Doctor of Pharmacy Honorary Member of the American Gastroenterological Association
In 1989, he founded R-Tech Ueno, Ltd. in Japan (listed on JASDAQ), and in 1996, he moved to the United States and founded Scampo Pharmaceuticals, Inc. (listed on NASDAQ).
The company has developed and launched "Rescula Ophthalmic Solution" for glaucoma, which has helped more than 500,000 patients in over 45 countries, and "Amitiza Capsules" for chronic constipation, and continues to research and develop new drugs.

COO

Kazuya Goto

Born in Kagoshima, Japan
Graduated from Kyoto University School of Medicine　
Assistant Professor, Department of Dementia Control, Graduate School of Medicine, Kyoto University

During his doctoral program, he conducted research on differentiation into motor neurons at the Kyoto University iPS Cell Research Institute.Currently, he is conducting drug discovery research on aging-related diseases at the Department of Dementia Control, Graduate School of Medicine, Kyoto University.

Management Director

Yukiko Hashitera

CEO and co Founder of Phoenixi Co.Ltd.
MBA, Master of Public Health

After graduating of college of pharmacy, Yukiko Hashitera joined pharmaceutical industry and she was involved the development of glaucoma and chronic idiopathic constipation medicine as a researcher. In 2008 she succeeded the listing of R-Tech Ueno, Ltd. in Heracles Market (currently JASDAQ) as a CEO. She founded Phoenixi Co., Ltd. Incubator, which supports motivated young talents from different industries to establish audacious innovative startup.

Director of Business Development

Chihiro Takenoshita

Graduated from International Christian University
MBA from Keio University Graduate School of Business Administration (Wharton Exchange Program)
Currently enrolled in a PhD program in Public Health.
Joined Nippon Zoki Pharmaceutical Co., Ltd. in 2014, where she worked in sales and was in charge of healthtech new business development. As her life's work, she is engaged in supporting women's leadership development and healthcare and IT business creation through the establishment of the Japan chapter of Healthtech Women, a North American NPO, and the co-founding of Womb Business Incubator, an incubator in the healthcare and wellbeing field.

Advisory Board

Advisory Board Member

Masakazu Hattori

Born in Shizuoka, Japan
Graduated from Hokkaido University,Graduate School of Veterinary Medicine,Doctor of Veterinary Medicine, Veterinarian
Discovered senescence-associated T cells with Dr. Nagahiro Minato and colleagues in 2009, and has since been working to elucidate the function of these cells.
Specialized in immunology.
Currently, he is conducting applied research on immunosenescence and cancer immunity at the Department of Cancer Tissue Response Research, Graduate School of Medicine, Kyoto University.

IP Advisor

Misako Nakata

Director and Chief Intellectual Property Officer, VLP Therapeutics Japan Inc.
Co-founder and Intellectual Property Advisor, VLP Therapeutics Inc.
Research Fellow, Department of Dementia Control, Graduate School of Medicine, Kyoto University
She has been involved in intellectual property work since the early 1990s.
She was Chief Intellectual Property Officer at Scampo Group until 2016, where she was instrumental in the expansion of the company's global business. During that time, she was also appointed Representative Director of Scampo's Japanese subsidiary in 2004. She contributed to the research, development, partnering, and commercialization of Amitiza® (lubiprostone), a treatment for chronic constipation.

our
partner